These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21676887)

  • 1. TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers.
    Mani RS; Iyer MK; Cao Q; Brenner JC; Wang L; Ghosh A; Cao X; Lonigro RJ; Tomlins SA; Varambally S; Chinnaiyan AM
    Cancer Res; 2011 Aug; 71(16):5387-92. PubMed ID: 21676887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
    Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
    Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
    Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
    Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues.
    Tu JJ; Rohan S; Kao J; Kitabayashi N; Mathew S; Chen YT
    Mod Pathol; 2007 Sep; 20(9):921-8. PubMed ID: 17632455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the TMPRSS2-ERG gene fusion in prostate cancer.
    Tomlins SA; Laxman B; Varambally S; Cao X; Yu J; Helgeson BE; Cao Q; Prensner JR; Rubin MA; Shah RB; Mehra R; Chinnaiyan AM
    Neoplasia; 2008 Feb; 10(2):177-88. PubMed ID: 18283340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.
    Todorova K; Metodiev MV; Metodieva G; Mincheff M; Fernández N; Hayrabedyan S
    Horm Cancer; 2017 Feb; 8(1):28-48. PubMed ID: 28050800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer.
    Zammarchi F; Boutsalis G; Cartegni L
    PLoS One; 2013; 8(3):e49721. PubMed ID: 23472063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The progress of TMPRSS2-ETS gene fusions and their mechanism in prostate cancer].
    Guo XQ; Gui YT; Cai ZM
    Yi Chuan; 2011 Feb; 33(2):117-22. PubMed ID: 21377967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
    Mehra R; Tomlins SA; Yu J; Cao X; Wang L; Menon A; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
    Cancer Res; 2008 May; 68(10):3584-90. PubMed ID: 18483239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.
    Mertz KD; Setlur SR; Dhanasekaran SM; Demichelis F; Perner S; Tomlins S; Tchinda J; Laxman B; Vessella RL; Beroukhim R; Lee C; Chinnaiyan AM; Rubin MA
    Neoplasia; 2007 Mar; 9(3):200-6. PubMed ID: 17401460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
    Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
    Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.
    Mehra R; Tomlins SA; Shen R; Nadeem O; Wang L; Wei JT; Pienta KJ; Ghosh D; Rubin MA; Chinnaiyan AM; Shah RB
    Mod Pathol; 2007 May; 20(5):538-44. PubMed ID: 17334343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delineation of TMPRSS2-ERG splice variants in prostate cancer.
    Hu Y; Dobi A; Sreenath T; Cook C; Tadase AY; Ravindranath L; Cullen J; Furusato B; Chen Y; Thangapazham RL; Mohamed A; Sun C; Sesterhenn IA; McLeod DG; Petrovics G; Srivastava S
    Clin Cancer Res; 2008 Aug; 14(15):4719-25. PubMed ID: 18676740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
    Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
    J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China.
    Dong J; Xiao L; Sheng L; Xu J; Sun ZQ
    Asian Pac J Cancer Prev; 2014; 15(7):3099-103. PubMed ID: 24815454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions.
    Singareddy R; Semaan L; Conley-Lacomb MK; St John J; Powell K; Iyer M; Smith D; Heilbrun LK; Shi D; Sakr W; Cher ML; Chinni SR
    Mol Cancer Res; 2013 Nov; 11(11):1349-61. PubMed ID: 23918819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
    Linn DE; Bronson RT; Li Z
    PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.
    Gopalan A; Leversha MA; Satagopan JM; Zhou Q; Al-Ahmadie HA; Fine SW; Eastham JA; Scardino PT; Scher HI; Tickoo SK; Reuter VE; Gerald WL
    Cancer Res; 2009 Feb; 69(4):1400-6. PubMed ID: 19190343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
    Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
    Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.